(Q38959358)

8 September 2017

title

Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance (English)

1 reference

8 September 2017

1 reference

1 reference

Claudia Maria Hattinger

4

1 reference

8 September 2017

11

1 reference

8 September 2017

Rogier Versteeg

7

0 references

Piero Picci

object named as

Piero Picci

10

0 references

Francesca Michelacci

6

object named as

Francesca Michelacci

1 reference

8 September 2017

5

Marilù Fanelli

1 reference

8 September 2017

2

Elisa Tavanti

1 reference

8 September 2017

3

Serena Vella

1 reference

8 September 2017

Valeria Sero

1

1 reference

8 September 2017

Barbara Valsasina

8

1 reference

8 September 2017

Beth Gudeman

9

1 reference

8 September 2017

publication date

7 September 2014

1 reference

Investigational New Drugs

8 September 2017

published in

1 reference

8 September 2017

volume

32

1 reference

8 September 2017

issue

6

1 reference

8 September 2017

page(s)

1167-1180

1 reference

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

From Plk1 to Plk5: functional evolution of polo-like kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Polo-like kinase 1 as target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Normal cells, but not cancer cells, survive severe Plk1 depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Functional genome screen for therapeutic targets of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Redundancy of autocrine loops in human osteosarcoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Chemotherapy resistance in osteosarcoma: current challenges and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Emerging drugs for high-grade osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Osteosarcoma development and stem cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0158-6

Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer

21 January 2018

1 reference

12 December 2020

Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma

1 reference

12 December 2020

Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.

1 reference

12 December 2020

Establishment and characterization of multidrug-resistant human osteosarcoma cell lines.

1 reference

12 December 2020

BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity.

1 reference

12 December 2020

10.1007/S10637-014-0158-6

Identifiers

DOI

1 reference

Dimensions Publication ID

8 September 2017

1035561882

0 references

1 reference